Adient plc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Adient plc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Sep 30, 2018 | $17.44B | Nov 29, 2018 |
| FY2018 | Sep 30, 2017 | $16.21B | Nov 29, 2018 |
| FY2018 | Sep 30, 2016 | $16.79B | Nov 29, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $14.54B | Nov 18, 2025 |
| FY2025 | Sep 30, 2024 | $14.69B | Nov 18, 2025 |
| FY2025 | Sep 30, 2023 | $15.40B | Nov 18, 2025 |
| FY2024 | Sep 30, 2022 | $14.12B | Nov 18, 2024 |
| FY2023 | Sep 30, 2021 | $13.68B | Nov 17, 2023 |
| FY2022 | Sep 30, 2020 | $12.67B | Nov 22, 2022 |
| FY2021 | Sep 30, 2019 | $16.53B | Nov 23, 2021 |
| FY2020 | Sep 30, 2018 | $17.44B | Nov 30, 2020 |
| FY2019 | Sep 30, 2017 | $16.21B | Nov 22, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $961.00M | Nov 18, 2025 |
| FY2025 | Sep 30, 2024 | $928.00M | Nov 18, 2025 |
| FY2025 | Sep 30, 2023 | $1.03B | Nov 18, 2025 |
| FY2024 | Sep 30, 2022 | $807.00M | Nov 18, 2024 |
| FY2023 | Sep 30, 2021 | $826.00M | Nov 17, 2023 |
| FY2022 | Sep 30, 2020 | $592.00M | Nov 22, 2022 |
| FY2021 | Sep 30, 2019 | $801.00M | Nov 23, 2021 |
| FY2020 | Sep 30, 2018 | $904.00M | Nov 30, 2020 |
| FY2019 | Sep 30, 2017 | $1.40B | Nov 22, 2019 |
| FY2018 | Sep 30, 2016 | $1.61B | Nov 29, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($281.00M) | Nov 18, 2025 |
| FY2025 | Sep 30, 2024 | $18.00M | Nov 18, 2025 |
| FY2025 | Sep 30, 2023 | $205.00M | Nov 18, 2025 |
| FY2024 | Sep 30, 2022 | ($120.00M) | Nov 18, 2024 |
| FY2023 | Sep 30, 2021 | $1.11B | Nov 17, 2023 |
| FY2022 | Sep 30, 2020 | ($547.00M) | Nov 22, 2022 |
| FY2021 | Sep 30, 2019 | ($491.00M) | Nov 23, 2021 |
| FY2020 | Sep 30, 2018 | ($1.69B) | Nov 30, 2020 |
| FY2019 | Sep 30, 2017 | $877.00M | Nov 22, 2019 |
| FY2018 | Sep 30, 2016 | ($1.55B) | Nov 29, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $387.00M | Nov 18, 2025 |
| FY2025 | Sep 30, 2024 | $372.00M | Nov 18, 2025 |
| FY2025 | Sep 30, 2023 | $362.00M | Nov 18, 2025 |
| FY2024 | Sep 30, 2022 | $322.00M | Nov 18, 2024 |
| FY2023 | Sep 30, 2021 | $316.00M | Nov 17, 2023 |
| FY2022 | Sep 30, 2020 | $370.00M | Nov 22, 2022 |
| FY2021 | Sep 30, 2019 | $454.00M | Nov 23, 2021 |
| FY2020 | Sep 30, 2018 | $513.00M | Nov 30, 2020 |
| FY2019 | Sep 30, 2017 | $488.00M | Nov 22, 2019 |
| FY2018 | Sep 30, 2016 | $460.00M | Nov 29, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $522.00M | Nov 18, 2025 |
| FY2025 | Sep 30, 2024 | $507.00M | Nov 18, 2025 |
| FY2025 | Sep 30, 2023 | $554.00M | Nov 18, 2025 |
| FY2024 | Sep 30, 2022 | $598.00M | Nov 18, 2024 |
| FY2023 | Sep 30, 2021 | $537.00M | Nov 17, 2023 |
| FY2022 | Sep 30, 2020 | $558.00M | Nov 22, 2022 |
| FY2021 | Sep 30, 2019 | $671.00M | Nov 23, 2021 |
| FY2020 | Sep 30, 2018 | $730.00M | Nov 30, 2020 |
| FY2019 | Sep 30, 2017 | $729.00M | Nov 22, 2019 |
| FY2018 | Sep 30, 2016 | $1.22B | Nov 29, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $449.00M | Nov 18, 2025 |
| FY2025 | Sep 30, 2024 | $543.00M | Nov 18, 2025 |
| FY2025 | Sep 30, 2023 | $667.00M | Nov 18, 2025 |
| FY2024 | Sep 30, 2022 | $274.00M | Nov 18, 2024 |
| FY2023 | Sep 30, 2021 | $260.00M | Nov 17, 2023 |
| FY2022 | Sep 30, 2020 | $246.00M | Nov 22, 2022 |
| FY2021 | Sep 30, 2019 | $308.00M | Nov 23, 2021 |
| FY2020 | Sep 30, 2018 | $679.00M | Nov 30, 2020 |
| FY2019 | Sep 30, 2017 | $746.00M | Nov 22, 2019 |
| FY2018 | Sep 30, 2016 | ($1.03B) | Nov 29, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $8.95B | Nov 18, 2025 |
| FY2025 | Sep 30, 2024 | $9.35B | Nov 18, 2025 |
| FY2025 | Sep 30, 2023 | $9.42B | Nov 18, 2025 |
| FY2024 | Sep 30, 2022 | $9.16B | Nov 18, 2024 |
| FY2023 | Sep 30, 2021 | $10.78B | Nov 17, 2023 |
| FY2022 | Sep 30, 2020 | $10.26B | Nov 22, 2022 |
| FY2021 | Sep 30, 2019 | $10.34B | Nov 23, 2021 |
| FY2020 | Sep 30, 2018 | $10.94B | Nov 30, 2020 |
| FY2018 | Sep 30, 2017 | $13.17B | Nov 29, 2018 |
| FY2017 | Sep 30, 2016 | $12.96B | Nov 22, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $1.77B | Nov 18, 2025 |
| FY2025 | Sep 30, 2024 | $2.13B | Nov 18, 2025 |
| FY2024 | Sep 30, 2023 | $2.23B | Nov 18, 2024 |
| FY2023 | Sep 30, 2022 | $2.07B | Nov 17, 2023 |
| FY2022 | Sep 30, 2021 | $2.38B | Nov 22, 2022 |
| FY2021 | Sep 30, 2020 | $1.21B | Nov 23, 2021 |
| FY2020 | Sep 30, 2019 | $1.85B | Nov 30, 2020 |
| FY2019 | Sep 30, 2018 | $2.39B | Nov 22, 2019 |
| FY2018 | Sep 30, 2017 | $4.28B | Nov 29, 2018 |
| FY2017 | Sep 30, 2016 | $4.18B | Nov 22, 2017 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $1.81B | Nov 18, 2025 |
| FY2025 | Sep 30, 2024 | $2.16B | Nov 18, 2025 |
| FY2025 | Sep 30, 2023 | $2.09B | Nov 18, 2025 |
| FY2024 | Sep 30, 2022 | $2.06B | Nov 18, 2024 |
| FY2023 | Sep 30, 2021 | $2.21B | Nov 17, 2023 |
| FY2022 | Sep 30, 2020 | $2.06B | Nov 22, 2022 |
| FY2021 | Sep 30, 2019 | $2.15B | Nov 23, 2021 |
| FY2020 | Sep 30, 2018 | $2.18B | Nov 30, 2020 |
| FY2019 | Sep 30, 2017 | $2.52B | Nov 22, 2019 |
| FY2018 | Sep 30, 2016 | $2.18B | Nov 29, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($1.17B) | Nov 18, 2025 |
| FY2025 | Sep 30, 2024 | ($885.00M) | Nov 18, 2025 |
| FY2024 | Sep 30, 2023 | ($903.00M) | Nov 18, 2024 |
| FY2023 | Sep 30, 2022 | ($1.11B) | Nov 17, 2023 |
| FY2022 | Sep 30, 2021 | ($988.00M) | Nov 22, 2022 |
| FY2021 | Sep 30, 2020 | ($2.10B) | Nov 23, 2021 |
| FY2020 | Sep 30, 2019 | ($1.55B) | Nov 30, 2020 |
| FY2019 | Sep 30, 2018 | ($1.03B) | Nov 22, 2019 |
| FY2018 | Sep 30, 2017 | $734.00M | Nov 29, 2018 |
| FY2017 | Sep 30, 2016 | $0 | Nov 22, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Sep 30, 2019 | $924.00M | Nov 22, 2019 |
| FY2019 | Sep 30, 2018 | $687.00M | Nov 22, 2019 |
| FY2019 | Sep 30, 2017 | $709.00M | Nov 22, 2019 |
| FY2019 | Sep 30, 2016 | $105.00M | Nov 22, 2019 |
| FY2018 | Sep 30, 2015 | $44.00M | Nov 29, 2018 |
| FY2017 | Sep 30, 2014 | $45.00M | Nov 22, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | (3) | Nov 18, 2025 |
| FY2025 | Sep 30, 2024 | 0 | Nov 18, 2025 |
| FY2025 | Sep 30, 2023 | 2 | Nov 18, 2025 |
| FY2024 | Sep 30, 2022 | (1) | Nov 18, 2024 |
| FY2023 | Sep 30, 2021 | 11 | Nov 17, 2023 |
| FY2022 | Sep 30, 2020 | (5) | Nov 22, 2022 |
| FY2021 | Sep 30, 2019 | (5) | Nov 23, 2021 |
| FY2020 | Sep 30, 2018 | (18) | Nov 30, 2020 |
| FY2019 | Sep 30, 2017 | 9 | Nov 22, 2019 |
| FY2018 | Sep 30, 2016 | (16) | Nov 29, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | (3) | Nov 18, 2025 |
| FY2025 | Sep 30, 2024 | 0 | Nov 18, 2025 |
| FY2025 | Sep 30, 2023 | 2 | Nov 18, 2025 |
| FY2024 | Sep 30, 2022 | (1) | Nov 18, 2024 |
| FY2023 | Sep 30, 2021 | 11 | Nov 17, 2023 |
| FY2022 | Sep 30, 2020 | (5) | Nov 22, 2022 |
| FY2021 | Sep 30, 2019 | (5) | Nov 23, 2021 |
| FY2020 | Sep 30, 2018 | (18) | Nov 30, 2020 |
| FY2019 | Sep 30, 2017 | 9 | Nov 22, 2019 |
| FY2018 | Sep 30, 2016 | (16) | Nov 29, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 79.15M | Nov 18, 2025 |
| FY2024 | Sep 30, 2024 | 84.87M | Nov 18, 2024 |
| FY2023 | Sep 30, 2023 | 93.70M | Nov 17, 2023 |
| FY2022 | Sep 30, 2022 | 94.86M | Nov 22, 2022 |
| FY2021 | Sep 30, 2021 | 94.38M | Nov 23, 2021 |
| FY2020 | Sep 30, 2020 | 93.89M | Nov 30, 2020 |
| FY2019 | Sep 30, 2019 | 93.62M | Nov 22, 2019 |
| FY2018 | Sep 30, 2018 | 93.40M | Nov 29, 2018 |
| FY2017 | Sep 30, 2017 | 93.14M | Nov 22, 2017 |
| FY2017 | Sep 30, 2016 | 0 | Nov 22, 2017 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Sep 30, 2021 | $0 | Nov 23, 2021 |
| FY2021 | Sep 30, 2020 | $0 | Nov 23, 2021 |
| FY2021 | Sep 30, 2019 | $26.00M | Nov 23, 2021 |
| FY2020 | Sep 30, 2018 | $103.00M | Nov 30, 2020 |